Effect of weekly 17-hydroxyprogesterone caproate on small for gestational age among pregnant women with HIV in Zambia. (15th November 2022)

• Record Type: Journal Article
• Authors: Conner, Madelyn G.; Vwalika, Bellington; Freeman, Bethany L.; Sebastião, Yuri V.; Mabula-Bwalya, Chileshe M.; Cole, Stephen R.; Stringer, Elizabeth M.; Kasaro, Margaret P.; Stringer, Jeffrey S.A.; Price, Joan T.
• Is Part Of: AIDS. Volume 36:Number 14(2022)
• Page Start: 2079
• Page End: 2081
• Publication Date: 2022-11-15
• Subjects: AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodicals; Periodicals; 616.9792005
• DOI: 10.1097/QAD.0000000000003362
• Languages: English
• ISSNs: 0269-9370

Abstract

Abstract : The IPOP trial demonstrated a reduced risk of severe small for gestational age among infants born to women with HIV who received weekly intramuscular 17 alpha-hydroxyprogesterone caproate. This secondary analysis examined the 17P treatment effect in subgroups of maternal BMI, parity, timing of antiretroviral therapy (ART) initiation, and ART regimen. We found that 17P was more effective among nulliparous women, women who started ART before pregnancy, and those taking protease inhibitors.